hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06314269, orgStudyIdInfo id: 246810121416, briefTitle: Incidence of Perioperative Cerebrovascular Stroke in Assuit University Hospitals, Hospital Based Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Stroke is the most common cause of disability in elderly people (over 65years of age) and the third most common cause of death in the world . The World Health Organization estimates that one in six people globally will suffer from stroke in their lifetime.Perioperative stroke is the most unwanted complication for patients, as well as for surgeons and anesthesiologists . The reported risk of perioperative stroke varies with the type of surgery. Its incidence is generally not high (approximate 0.1-1.9%) in non-cardiac, non-neurologic, and non-major surgery However, it may occur in up to 10% of patients undergoing high-risk cardiac or brain surgery . Patients with perioperative stroke are less likely to have a good functional outcome and have an eight-fold higher mortality compared with those without perioperative stroke, conditionsModule conditions: Perioperative Complication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 1, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: 1- To determine incidence and prevalence of perioperative cerebrvosacular stroke in General surgery, cardiothorasic surgery and vascular surgery departments, Assuit university hospitalis, Egypt., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06314256, orgStudyIdInfo id: 2023/218, briefTitle: Clinical Evaluation of Hyaluronic Acid and Platelet Rich Fibrin Injection Efficacy in Interdental Papilla Reconstruction, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-10-10, completionDateStruct date: 2024-11-10, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Altinbas University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate and compare the efficacy of injectable platelet rich fibrin (i-PRF) and hyaluronic acid (HA) in reconstruction of interdental papilla loss. The main questions it aims to answer are:* How compareable are above mentioned two interventions (i-PRF\&HA) in reconstruction of interdental papilla loss?* Which treatment option is better accepted by patients? Which treatment option would patients be more satisfied with? Participants with multiple interdental papilla loss will be treated with both i-PRF and HA in split-mouth design. Researchers will compare two treatment options to see if black triangles caused by interdental papilla loss closes and if yes, for how long do they last., conditionsModule conditions: Interdental Papilla Loss, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A type of study used frequently in oral research: the mouth is divided into two or more subunits. Active and control (comparison) treatments are applied to the subunits (e.g., to the left and right sides)., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Participant will be masked which side of her/his mouth treated with either i-PRF or HA., whoMasked: PARTICIPANT, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Injection, interventions name: Injection, outcomesModule primaryOutcomes measure: Reduction in Black Triangle Area, primaryOutcomes measure: Reduction in Black Triangle Height, primaryOutcomes measure: Reduction in Black Triangle Width, secondaryOutcomes measure: Volume Gain of Interdental Papilla, secondaryOutcomes measure: Patient Satisfaction Score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Altinbas University, status: RECRUITING, city: Istanbul, country: Turkey, contacts name: Baris Impram, role: CONTACT, phone: +905343148500, email: barisimpram@gmail.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06314243, orgStudyIdInfo id: RHDIRB2020110301 REC #241, briefTitle: The Impact of Pumpkin Seed Oil Supplementation on Hemodialysis Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to investigate the effects of Pumpkin Seed Oil (PSO) supplementation on systemic inflammation, oxidative stress, and lipid profile in hemodialysis patients.The main question it aims to answer is:• Does PSO have a promising effect on systemic inflammation, oxidative stress, and lipid profile in hemodialysis patients?Patients on regular hemodialysis who take PSO supplementation will be compared to those who don't to see if PSO supplementation improves their systemic inflammation, oxidative stress, and lipid profile., conditionsModule conditions: Hemodialysis Patients, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Design: Prospective, randomized, Open label - controlled clinical trial.Patients: A total of 56 patients on regular hemodialysis (HD) will be enrolled in the study. These patients will be randomly allocated into two equal groups:* Group 1 (PSO group): consists of 28 patients who will receive one capsule containing 1010 mg PSO once daily for 12 weeks, " Ronkin®, KMT PHARMA, Egypt. "* Group 2 (Control group): consists of 28 patients who will not receive the intervention., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 56, type: ESTIMATED, armsInterventionsModule interventions name: Pumpkin Seed Oil " Ronkin®, KMT PHARMA, Egypt. ", outcomesModule primaryOutcomes measure: To evaluate the effect of PSO supplementation on oxidative stress in hemodialysis patients., primaryOutcomes measure: To evaluate the effect of PSO supplementation on the systemic inflammation in hemodialysis patients., secondaryOutcomes measure: To evaluate the effect of PSO supplementation on the lipid profile in hemodialysis patients., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06314230, orgStudyIdInfo id: AUSCAD, briefTitle: Australian Genomics Of Chronic Allograft Dysfunction Study, acronym: AUSCAD, statusModule overallStatus: RECRUITING, startDateStruct date: 2012-04-26, primaryCompletionDateStruct date: 2040-01-01, completionDateStruct date: 2040-01-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Western Sydney Local Health District, class: OTHER, descriptionModule briefSummary: The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles., conditionsModule conditions: Kidney Transplant Rejection, conditions: Kidney Transplant; Complications, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Graft failure, primaryOutcomes measure: Allograft rejection, primaryOutcomes measure: Gene profile, secondaryOutcomes measure: Death, secondaryOutcomes measure: Major infectious adverse outcomes, secondaryOutcomes measure: Major malignancy related adverse outcomes, secondaryOutcomes measure: Major cardiovascular adverse outcomes, secondaryOutcomes measure: Chronic allograft dysfunction, secondaryOutcomes measure: BK virus associated nephropathy, secondaryOutcomes measure: Albuminuria, secondaryOutcomes measure: Surrogate end-points, secondaryOutcomes measure: Delayed graft function (DGF), secondaryOutcomes measure: Death censored graft loss (DCGL), secondaryOutcomes measure: Treatment resistant rejection, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Westmead Hospital, status: RECRUITING, city: Westmead, state: New South Wales, zip: 2145, country: Australia, contacts name: Jennifer SY Li, MBBS, FRACP, role: CONTACT, email: jennifer.li@health.nsw.gov.au, geoPoint lat: -33.80383, lon: 150.98768, locations facility: Westmead Institute for Medical Research, status: RECRUITING, city: Westmead, state: New South Wales, zip: 2145, country: Australia, contacts name: Philip J O'Connell, MBBS, FRACP, role: CONTACT, email: philip.oconnell@sydney.edu.au, geoPoint lat: -33.80383, lon: 150.98768, hasResults: False
protocolSection identificationModule nctId: NCT06314217, orgStudyIdInfo id: CL-00002, secondaryIdInfos id: 202330714, type: REGISTRY, domain: MOH ISRAEL, briefTitle: Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-18, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-03-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Everads Therapy, class: INDUSTRY, descriptionModule briefSummary: This is an open-label pilot device study. The aim of the study is to evaluate the safety and performance of Everads Injector following single injection of suspension approved for ocular use into the suprachoroidal space.The study population is patients diagnosed with diabetic macular edema (DME) that were previously treated. 10 adult subjects are expected to be enrolled based on the inclusion-exclusion criteria.The study will involve 6 visits during a period of 6 weeks, conditionsModule conditions: Diabetic Macular Edema, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Everads Injector: For targeted suprachoroidal delivery of therapy, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Everads Injector, outcomesModule primaryOutcomes measure: Frequency of treatment-emergent adverse events, primaryOutcomes measure: Frequency of adverse device effects, secondaryOutcomes measure: Confirmation of TA delivery into the suprachoroidal space, secondaryOutcomes measure: Change from baseline in central macular thickness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rambam MC, status: RECRUITING, city: Haifa, country: Israel, contacts name: Meital Abecassis, role: CONTACT, phone: 047772668, contacts name: Yoreh Barak, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.81841, lon: 34.9885, hasResults: False
protocolSection identificationModule nctId: NCT06314178, orgStudyIdInfo id: p-2024-15469, briefTitle: Assessing Demographic Biases in Deep Learning Model for Fetal Growth Estimation in Clinical Practice. Patients Eligible for Inclusion Are Women With a Gestational Age Between 24-42 Weeks Undergoing a Third-trimester Growth Scan. The Image Data From the Scan Are Used to Calculate Fetal Weight., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Copenhagen Academy for Medical Education and Simulation, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to compare a new artificial intelligence (AI) feedback tool with the traditional method for estimating fetal weight during ultrasound scans on pregnant women between 24-42 weeks of gestation. The study aims to investigate the presence of demographic bias in the AI model. The demographic factors examined in the study include Body Mass Index (BMI), the number of births, fetal age, mother\&#39;s age, fetal sex, and the presence of preeclampsia. Moreover, the study will compare the accuracy of the AI model and the Hadlock model, a fetal growth formula, in estimating fetal weight. Participants will have their ultrasound scans pseudonymized and securely stored on password-protected removable drives, ensuring their identity and privacy are maintained. Afterward, the ultrasound data will be sent to the Technical University of Denmark (DTU), where the AI model will analyze the images to estimate fetal weight., conditionsModule conditions: Pregnancy Complications, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Demographic biases, secondaryOutcomes measure: Comparing the accuracy of the Hadlock formula and the AI model, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06314165, orgStudyIdInfo id: PamukkaleU-SBE-RND-01, briefTitle: Evaluation of the Effect of Music Medicine Application on Menstrual Symptoms, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Pamukkale University, class: OTHER, descriptionModule briefSummary: In this study, the "Music Medicine Application" method was chosen in line with the literature and guidelines and it is aimed to determine whether it is effective in reducing the symptoms experienced by female students with "Music Medicine Application" during the menstrual period., conditionsModule conditions: Menstruation; Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two groups: comparative experiment and control, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Participants included in the study will not know which group they are in. In this way, the study will be carried out in a single-blind manner., whoMasked: PARTICIPANT, enrollmentInfo count: 62, type: ESTIMATED, armsInterventionsModule interventions name: music medicine practice, outcomesModule primaryOutcomes measure: menstruation symptom scale, secondaryOutcomes measure: Visual Analogue Scale, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pamukkale University Faculty of Health Sciences, status: RECRUITING, city: Denizli, zip: 20180, country: Turkey, contacts name: Rabia Nur Doğan, role: CONTACT, phone: +905528400797, email: rabianur_1997@hotmail.com, geoPoint lat: 37.77417, lon: 29.0875, hasResults: False
protocolSection identificationModule nctId: NCT06314152, orgStudyIdInfo id: 2023032, briefTitle: 3-point With 1-point Mesh Fixation in TAPP for Inguinal Hernia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2024-10-10, completionDateStruct date: 2024-10-10, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Nanchong Central Hospital, class: OTHER_GOV, collaborators name: Guang'an People's Hospital, collaborators name: Pengan County People's Hospital, collaborators name: People's Hospital of Yilong County, collaborators name: Nanbu Hospital of County Chinese Medicine, collaborators name: Langzhong People's Hospital, collaborators name: Langzhong Traditional Chinese Medicine Hospital, descriptionModule briefSummary: This study was designed to compare the outcome of 3 point with 1 point lightweight mesh fixation in TAPP surgery for patients with inguinal hernia. The main outcome include seroma, chronic pain, recurrence, et al., conditionsModule conditions: Inguinal Hernia, conditions: Chronic Pain, conditions: Seroma, conditions: Recurrent, conditions: Infections, conditions: Hematoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 337, type: ESTIMATED, armsInterventionsModule interventions name: Lightweight mesh fixation in 3 points or 1 point, outcomesModule primaryOutcomes measure: Rate of recurrence, primaryOutcomes measure: Rate of postoperative pain, secondaryOutcomes measure: Rate of postoperative complications, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yunhong Tian, status: RECRUITING, city: Nanchong, state: Sichuan, zip: 637000, country: China, contacts name: Yunhong Tian, PHD, role: CONTACT, phone: 13508087719, email: drtianyunhong@126.com, geoPoint lat: 30.79508, lon: 106.08473, hasResults: False
protocolSection identificationModule nctId: NCT06314113, orgStudyIdInfo id: EGCG-HPV, briefTitle: Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection, acronym: EGCG-HPV, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Palermo, class: OTHER, descriptionModule briefSummary: The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection., conditionsModule conditions: Low-Grade Intraepithelial Neoplasia of Cervix, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Epigallocatechin Gallate, outcomesModule primaryOutcomes measure: Persistence, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: "Paolo Giaccone" Hospital, status: RECRUITING, city: Palermo, zip: 90127, country: Italy, contacts name: Antonio Simone Laganà, M.D., Ph.D., role: CONTACT, phone: +39 3296279579, email: antoniosimone.lagana@unipa.it, contacts name: Giuseppe Mascellino, M.D., role: SUB_INVESTIGATOR, contacts name: Pietro Serra, M.D., role: SUB_INVESTIGATOR, contacts name: Andrea Etrusco, M.D., role: SUB_INVESTIGATOR, geoPoint lat: 38.13205, lon: 13.33561, hasResults: False
protocolSection identificationModule nctId: NCT06314100, orgStudyIdInfo id: IP-2020-02-4027-EB, briefTitle: The Effect of Aerosol Formed From Tobacco Heating Systems on the Microbiome of Supragingival Dental Biofilm, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-10-01, primaryCompletionDateStruct date: 2023-10-25, completionDateStruct date: 2023-10-25, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Rijeka, class: OTHER, collaborators name: Croatian Science Foundation, descriptionModule briefSummary: Dental caries is a multifactorial disease primarily caused by supragingival dental biofilm. Its progression is influenced by many environmental factors, which include smoking. Tobacco heating systems (THS) are a novel tobacco product whose effect on the microbiome of the supragingival dental biofilm has not yet been investigated.The aim of the proposed research is to determine and compare the composition of the microbiomes of the supragingival dental biofilm of THS smokers, cigarette smokers, and nonsmokers using the Next Generation Sequencing method and to assess and compare the risk of new caries lesion formation between the test groups using the Cariogram method.The results of this research will provide insight into changes in the microbiome of the supragingival dental biofilm resulting from exposure to aerosols from tobacco combustion and tobacco heating., conditionsModule conditions: Dental Caries, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Tobacco heating systems, interventions name: cigarette smoking, interventions name: non smoking, outcomesModule primaryOutcomes measure: diversity of bacterial species, primaryOutcomes measure: abundance of bacterial species, primaryOutcomes measure: caries risk, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of dental medicine, University of Rijeka, city: Rijeka, country: Croatia, geoPoint lat: 45.32674, lon: 14.44239, hasResults: False
protocolSection identificationModule nctId: NCT06314087, orgStudyIdInfo id: Neoantigen Radiotherapy, briefTitle: iTAPVR Study - Phase II Randomized Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: The University of Hong Kong-Shenzhen Hospital, class: OTHER, descriptionModule briefSummary: In this study, the investigators provide an individualized tumor neoantigen peptide vaccine in combination with radiotherapy to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the individualized tumor neoantigen peptide vaccine in combination with radiotherapy, conditionsModule conditions: Advanced Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: Randomized, enrollmentInfo count: 154, type: ESTIMATED, armsInterventionsModule interventions name: Placebo + conventional treatment including radiotherapy, interventions name: Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine, outcomesModule primaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False